Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The FDA has eliminated Risk Evaluation and Mitigation Strategies for all currently approved BCMA- and CD19-directed autologous CAR-T cell immunotherapies, determining that the safety program is no ...

Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.

The US Food and Drug Administration has approved Yeztugo (lenacapavir), an injectable HIV-1 capsid inhibitor, as preexposure prophylaxis (PrEP) to reduce the risk for sexually acquired HIV.

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away ...

Objective Guidelines for antipsychotic use in first-episode psychosis (FEP) recommend that medication be chosen initially on the basis of side effect profile with doses at the lower end of the range.

Two AS01-adjuvanted vaccines for different pathogens -- the respiratory syncytial virus (RSV) vaccine (Arexvy) and the ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...